

Patent

Atty. Docket No.: 0101-UTL-0

In re patent application of:

AMYLIN PHARMACEUTICALS, INC.

Group Art Unit: 1632**Applicants:** Gedulin et al.**Examiner:** To be assigned**Serial No.:** 10/671,304**Filed:** September 24, 2003**Title:** Treatment of Pancreatitis with Amylin**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.56, the documents listed on the attached Form PTO/SB/08 are being submitted herewith for consideration by the Examiner. A copy of each of the listed items is included herewith. The reference Schmidt *et al.*, Dtsch Med Wochenschr (1971), 96 1773-1775, is in German. An English translation of the reference or an English abstract (such as from Derwent) is not available. In essence, the reference purports to show that calcitonin decreases secretions of the pancreas, as shown in Tab. 1.

The references are being cited only in the interest of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

This IDS is believed to be timely in that it is being submitted under 37 C.F.R. § 1.97(b)(3), that is before the mailing of a first Office action on the merits. Thus, no petition or

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 1, 2004
Date of Deposit

Diane Trus
Name of Person Mailing Paper
Diane Trus
Signature of Person Mailing Paper

Information Disclosure Statement

Serial No. 10/671,304

Page 2 of 2


fee is required. However, if the undersigned is in error in this regard, then it is requested that the Office consider this IDS as filed under 37 C.F.R. § 1.97(c).

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of this and any additional fees associated with this communication or credit any overpayment to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 8/30/2004

By: 
Mi K. Kim
Registration No. 44,830

AMYLIN PHARMACEUTICAL, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/671,304
		Filing Date	September 24, 2003
		First Named Inventor	Gedulin et al.
		Art Unit	1632
		Examiner Name	Not assigned yet
Sheet 1	of 2	Attorney Docket Number	0101-UTL-0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRAND et al. , Int. J. Gastrointest Cancer (2002) 31(1-3): 123-128	
		CLARK et al. , Diabetes Res Clin Pract. (1995) Aug 28 Suppl.: S39-47	
		GARG et al., Diabetes Care (1996) Jan 19 (1): 28-31.	
		GASIOROWSKA et al. , Hepatogastroenterology (2003) Jan-Feb 50(49): 258-262.	
		GEDULIN et al., Diabetes (1998) 47 (Suppl 1), abstract 1086.	
		GOEBELL et al., Scand J Gastroenterol (1979) 14: 881-889	
		GOEBELL, Demeter Verleg (1976): 28-31	
		GOEBELL, Excerpta Medica (1981), Int. Cong. Ser. 540, 346-351	
		HOTZ et al. , Res Exp Med (Berl) 1973, 160 152-165	
		LUISETTO, Excerpta Medica (1981), Int. Cong. Ser. 540, 336-345	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/671,304
		Filing Date	September 24, 2003
		First Named Inventor	Gedulin et al.
		Art Unit	1632
		Examiner Name	Not assigned yet
Sheet 2	of 2	Attorney Docket Number	0101-UTL-0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MORLEY et al. , Peptides (1991) 12:865-869.	
		ODES et al., S. Afr. Med J. (1978) 53, 201-203	
		PAUL, Dtsch Med Wochenschr (1979) 104, 615-622	
		PHILLIPS et al., Eur Surg Res (1999) 31(6): 457-464.	
		PHILLIPS et al., Pancreas (2000) Jan 20(1):105-106.	
		SCHMIDT, Dtsch Med Wochenschr (1971), 96 1773-1775	
		YOUNG, A.A., et al. Diabetologia (1995) 38:642-648.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.